… ProQR Announces Second Quarter 2020 Operating and Financial Results Positive preliminary data … financial statements, the potential exercise of share options is not included in the diluted earnings per share … Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal in …
… In November, the first patient was dosed in the Phase 1/2 open-label trial (PQ-110-001) to assess the safety, … six adults (≥ 18 years) who have LCA 10 due to one or two copies of the p.Cys998X mutation in the CEP290 gene. During … expertise in genetic retinal disease in the U.S. and Europe. The objectives of the trial include safety, …
… that it further strengthened its leading intellectual property estate for ADAR-mediated RNA editing by successfully defending against an opposition filed in Japan by a strawman against ProQR’s … in mice in vivo via modulation of ANGPLT3 protein properties leading to favorable increase in LPL enzymatic …
… visual acuity, visual fields, and the objective measure of optical coherence tomography (OCT) retinal imaging, after a … – Axiomer ® and Trident ® ProQR has been further optimizing the Axiomer ® Editing Oligonucleotide (EON) … editing levels in retinal organoid models. ProQR will develop selected genetic eye disease targets with Axiomer ® , …